التفاصيل البيبلوغرافية
| العنوان: |
Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study |
| المؤلفون: |
Van Name, Michelle A., Kanapka, Lauren G., DiMeglio, Linda A., Miller, Kellee M., Albanese-O’Neill, Anastasia, Commissariat, Persis, Corathers, Sarah D., Harrington, Kara R., Hilliard, Marisa E., Anderson, Barbara J., Kelley, Jennifer C., Laffel, Lori M., MacLeish, Sarah A., Nathan, Brandon M., Tamborlane, William V., Wadwa, R. Paul, Willi, Steven M., Williams, Kristen M., Wintergerst, Kupper A., Woerner, Stephanie, Wong, Jenise C., DeSalvo, Daniel J. |
| المساهمون: |
Leona M. and Harry B. Helmsley Charitable Trust |
| المصدر: |
Journal of Diabetes Science and Technology ; volume 17, issue 4, page 976-987 ; ISSN 1932-2968 1932-2968 |
| بيانات النشر: |
SAGE Publications |
| سنة النشر: |
2022 |
| مصطلحات موضوعية: |
Biomedical Engineering, Bioengineering, Endocrinology, Diabetes and Metabolism, Internal Medicine |
| الوصف: |
Objectives: Achieving optimal glycemic outcomes in young children with type 1 diabetes (T1D) is challenging. This study examined the durability of continuous glucose monitoring (CGM) coupled with a family behavioral intervention (FBI) to improve glycemia. Study Design: This one-year study included an initial 26-week randomized controlled trial of CGM with FBI ( CGM+FBI) and CGM alone ( Standard-CGM) compared with blood glucose monitoring (BGM), followed by a 26-week extension phase wherein the BGM Group received the CGM+FBI ( BGM-Crossover) and both original CGM groups continued this technology. Results: Time in range (70-180 mg/dL) did not improve with CGM use (CGM+FBI: baseline 37%, 52 weeks 41%; Standard-CGM: baseline 41%, 52 weeks 44%; BGM-Crossover: 26 weeks 38%, 52 weeks 40%). All three groups sustained decreases in hypoglycemia (<70 mg/dL) with CGM use (CGM+FBI: baseline 3.4%, 52 weeks 2.0%; Standard-CGM: baseline 4.1%, 52 weeks 2.1%; BGM-Crossover: 26 weeks 4.5%, 52 weeks 1.7%, P-values <.001). Hemoglobin A1c was unchanged with CGM use (CGM+FBI: baseline 8.3%, 52 weeks 8.2%; Standard-CGM: baseline 8.2%, 52 weeks 8.0%; BGM-Crossover: 26 weeks 8.1%, 52 weeks 8.3%). Sensor use remained high (52-week study visit: CGM+FBI 91%, Standard-CGM 92%, BGM-Crossover 88%). Conclusion: Over 12 months young children with T1D using newer CGM technology sustained reductions in hypoglycemia and, in contrast to prior studies, persistently wore CGM. However, pervasive hyperglycemia remained unmitigated. This indicates an urgent need for further advances in diabetes technology, behavioral support, and diabetes management educational approaches to optimize glycemia in young children. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1177/19322968221084667 |
| الإتاحة: |
https://doi.org/10.1177/19322968221084667Test |
| حقوق: |
http://journals.sagepub.com/page/policies/text-and-data-mining-licenseTest |
| رقم الانضمام: |
edsbas.642EA713 |
| قاعدة البيانات: |
BASE |
